BBI

Utilizing Built-In Antimicrobial Technology to Support Surface Hygiene and Cleanliness in Food Processing Environments, Webinar Presented by Microban®, Hosted by Xtalks

Retrieved on: 
Monday, September 27, 2021
Technology, Adoption, Cleanliness, BBI, Hygiene, Food, Microbiology, Fancy Ultra Fresh, Food contact materials, Regulatory affairs, Element, Bacteria, Method, Growth, Science, Asia, Industry, Food preservation

Integration of antimicrobial surfaces can support a wider approach to hygiene.

Key Points: 
  • Integration of antimicrobial surfaces can support a wider approach to hygiene.
  • Built-in antimicrobial technologies have been shown to provide durable and complementary surface protection against bacteria, mold and mildew growth.
  • These formulations become a permanent feature of a product, enabling manufacturing facilities to maintain hygienically cleaner food processing environments and working to support regular cleaning protocols.
  • For more information, or to register for this event, visit Utilizing Built-In Antimicrobial Technology to Support Surface Hygiene and Cleanliness in Food Processing Environments.

Blumenthal Brands Integrated, LLC and Tide Water Oil Co. (India) Ltd. Announce the beginning of a Licensed Manufacturing Partnership

Retrieved on: 
Thursday, September 23, 2021
TWO, Partnership, BBI, Lubricant, Efficiency, Miss Veedol, Oil India Ltd FC, Marketing, LLC, Technology, DIY, Speciality chemicals

BBI-TWO, together, have planned an initial rollout of imported GUNK & LIQUID WRENCH degreasers, absorbents, lubricants, penetrants, rust removers, greases, and corrosion inhibitors.

Key Points: 
  • BBI-TWO, together, have planned an initial rollout of imported GUNK & LIQUID WRENCH degreasers, absorbents, lubricants, penetrants, rust removers, greases, and corrosion inhibitors.
  • BBI's commitment to global expansion of its legendary brands through regional manufacturing and distribution is reaffirmed by this partnership.
  • Tide Water Oil, headquartered in Kolkata, India, is a leading player in the Indian lubricant industry since 1928.
  • The Charlotte, NC, USA-based Blumenthal Brands Integrated, LLC formulates, markets and distributes high-performance chemicals under the brand names GUNK, LIQUID WRENCH and TITESEAL.

Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity

Retrieved on: 
Friday, September 17, 2021
Precision medicine, Massachusetts, Autoimmunity, Hyperhidrosis, Intellectual property, Inflammation, Virginia Mason Medical Center, Humanitarian use licenses, KOL, Benaroya Research Institute, Investor, Massachusetts Institute of Technology, DYRK1A, Patient, Down syndrome, Nasdaq, Technology, Clinical trial, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Harvard Medical School, Assistant, Hospital, Therapy, Transfusion medicine, Rheumatoid arthritis, Washington University in St. Louis, Clinical pathology, COVID-19, Dual, Degenerative disease, EDT, GLOBE, Massachusetts General Hospital, Atopic dermatitis, SEC, Research, Time, BBI, Leadership, Pharmaceutical industry

Brickells management team will also provide a brief update on the Companys investigational DYRK1A inhibitor platform.

Key Points: 
  • Brickells management team will also provide a brief update on the Companys investigational DYRK1A inhibitor platform.
  • The webinar will be accessible via a webcast posted on the Events and Presentation page in the Investors section of Brickells website at https://ir.brickellbio.com/events-presentations .
  • For those unable to watch this broadcasted event live, a replay will be available on the Brickell website following the event.
  • The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.

GE Profile™ Introduces the First and Only Dishwasher that Helps Prevent Bacteria Growth

Retrieved on: 
Wednesday, September 1, 2021
Manufacturing, Home Goods, Other Manufacturing, Other Retail, Retail, Industry, GE Appliances, Technology, Growth, Hotpoint, International, Bacteria, Fungus, Science, Disinfectant, BBI, Time, Fancy Ultra Fresh, Asia, Multimedia, GE, Water, Atmosphere, Fresh water, HERE, Home appliance, Food preservation, Heating, ventilation, and air conditioning

Today GE Appliances, a Haier company, announced a revolutionary, new dishwasher, the GE Profile UltraFresh System Dishwasher with Microban Antimicrobial Technology that aims to reduce the growth of bacteria in and on your dishwasher

Key Points: 
  • Today GE Appliances, a Haier company, announced a revolutionary, new dishwasher, the GE Profile UltraFresh System Dishwasher with Microban Antimicrobial Technology that aims to reduce the growth of bacteria in and on your dishwasher
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210901005634/en/
    The new GE Profile UltraFresh System Dishwasher with Microban Antimicrobial Technology aims to reduce the growth of bacteria in and on your dishwasher.
  • DEFEND: GE Appliances is the exclusive dishwasher partner of Microban International, the global leader in antimicrobial additives and odor control solutions.
  • The GE Profile UltraFresh System Dishwasher with Microban Antimicrobial Technology includes a series of additional new features found HERE .

Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases

Retrieved on: 
Wednesday, September 1, 2021
DYRK1A, Trial of the century, Rheumatoid arthritis, SEC, Leadership, Research, Hyperhidrosis, Intellectual property, Precision medicine, Partnership, Bangalore Bio-Cluster, University, Transfection, Therapy, U.S. Securities and Exchange Commission, Large-cell lung carcinoma, Doctor of Philosophy, BBI, Lead, T helper cell, Humanitarian use licenses, Time, Degenerative disease, Clinical trial, Conference, JAK, Technology, MD, Nasdaq, Inflammation, Assistant, Autoimmunity, Affiliation, Translational medicine, Cytokine, Dermatology, Drug development, Company, Atopic dermatitis, University of Washington Department of Bioengineering, Acquisition, GLOBE, Immune system, Private Securities Litigation Reform Act, RET, Patient, Benaroya Research Institute, COVID-19, Pharmaceutical industry

BOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced it has entered into a definitive agreement with Voronoi Inc., a platform-based drug discovery company in South Korea dedicated to developing new kinase inhibitors, that grants Brickell exclusive, worldwide rights to research, develop and commercialize novel therapeutics generated from a proprietary DYRK1A inhibitor platform. These novel DYRK1A inhibitors aim to restore immune balance in patients whose immune system has become dysregulated, thus offering large potential across a wide array of autoimmune and inflammatory diseases.

Key Points: 
  • These novel DYRK1A inhibitors aim to restore immune balance in patients whose immune system has become dysregulated, thus offering large potential across a wide array of autoimmune and inflammatory diseases.
  • Notably, many current therapies for autoimmune disorders are broadly immunosuppressant, which may lead to severe side effects, such as increased infection risk.
  • We are excited to announce the partnering of our novel DYRK1A inhibitor platform with Brickell, said Daekwon Kim, Chief Executive Officer of Voronoi.
  • Brickell will be responsible for all future development activities and expenses related to the DYRK1A inhibitor platform.

Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer

Retrieved on: 
Wednesday, September 1, 2021
College of Medicine, DYRK1A, Innovation and Entrepreneurship Group, University, Medicine, George Washington University, Therapy, Strategic planning, U.S. Securities and Exchange Commission, Acquisition, GLOBE, SEC, Leadership, Drug, Rheumatology, Biology, Research, Nasdaq, Private Securities Litigation Reform Act, BBI, Hyperhidrosis, Humanitarian use licenses, Clinical, Stanford University, Time, Intellectual property, NDA, Autoimmunity, Outline of health sciences, Policy, Clinical trial, MBA, University of Maryland, College Park, Board, Degenerative disease, Immunology, Patient, Novartis, Trustee, M.B.A, COVID-19, Director, Dermatology, Drug development, MD, Pharmaceutical industry

In this new role, Dr. Luchi will oversee the Companys clinical development strategy and medical affairs functions.

Key Points: 
  • In this new role, Dr. Luchi will oversee the Companys clinical development strategy and medical affairs functions.
  • We are delighted to have Dr. Luchi join our team at this transformative point in our Companys history.
  • She was most recently working as the interim Chief Medical Officer and a Clinical Development consultant for the Bracken Group.
  • The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.

Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Retrieved on: 
Monday, August 16, 2021
Time, II, Intellectual property, Blood, Population, Clinical trial, University of Florida, Anticholinergic, Sweatpants, Exocrine gland, Company, Private Securities Litigation Reform Act, Safety, University, COVID-19, GLOBE, Research, Nervous system, Hyperhidrosis, BBI, SEC, NDA, U.S. Securities and Exchange Commission, Cardigan, Patient, Leadership, Development, Humanitarian use licenses, Nasdaq, Therapy, Acetylcholine, GSP, Prevalence, Graduate, Pharmaceutical industry

BOULDER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the final patient has completed the Phase 3 pivotal Cardigan II study, which is evaluating sofpironium bromide gel, 15% in patients with primary axillary (underarm) hyperhidrosis. The Company expects to announce topline results for the U.S. Phase 3 pivotal Cardigan I and Cardigan II studies concurrently in the fourth quarter of 2021. Pending the outcome of these studies, the Company expects to submit a New Drug Application (NDA) for sofpironium bromide gel, 15% to the U.S. FDA in mid-2022.

Key Points: 
  • Were excited to announce that all patients have now completed their final visits in the Cardigan I and Cardigan II studies of sofpironium bromide gel, 15% in patients with primary axillary hyperhidrosis.
  • Phase 3 clinical program for sofpironium bromide gel, 15% is comprised of two pivotal clinical studies, Cardigan I and Cardigan II.
  • Each study has enrolled approximately 350 subjects nine years of age and older with primary axillary hyperhidrosis.
  • The studies are multicenter, randomized, double-blinded, vehicle (placebo)-controlled studies evaluating the efficacy and safety of topically applied sofpironium bromide gel, 15%.

Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 12, 2021
Income, Time, Trial of the century, II, Intellectual property, Blood, Awareness, Population, Clinical trial, University of Florida, Anticholinergic, Sweatpants, Research, Exocrine gland, Company, Private Securities Litigation Reform Act, University, COVID-19, GLOBE, Forgiveness, Hyperhidrosis, BBI, SEC, Pharmacokinetics, NDA, Nervous system, FDA, U.S. Securities and Exchange Commission, Conference, Cardigan, Patient, Leadership, Perspiration, Humanitarian use licenses, PK, Nasdaq, Safety, Therapy, Acetylcholine, Prevalence, Graduate, Pharmaceutical industry

BOULDER, Colo., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • Research and development expenses were $8.8million for the second quarter of 2021, compared to $2.7million for the second quarter of 2020.
  • General and administrative expenses were $2.9million for the second quarter of 2021, compared to $3.0million for the second quarter of 2020.
  • Total other income, net was $0.4million for the second quarter of 2021, compared to $7thousand for the second quarter of 2020.
  • Brickells net loss was $11.1million for the second quarter of 2021 compared to $5.1million for the second quarter of 2020.

Bertelsmann Completes Acquisition of Crescera Stake in Afya; New Directors Appointed

Retrieved on: 
Thursday, August 5, 2021
Education, Health, Other Education, General Health, Continuing, Training, Investment, Deloitte, CEO, Board of directors, Board, Sale, EVP, Association, BMG, Bertelsmann, Venture capital, VC, Shobhna S Kumar, Music, Delhi University, Physician, Columbia Business School, Health, Student, BBI, Science and technology in Asia, Master, Education, Mathematics, Publishing

Since Afyas inception, Bertelsmann has indirectly held a stake in Afya through its investment in Crescera Educacional.

Key Points: 
  • Since Afyas inception, Bertelsmann has indirectly held a stake in Afya through its investment in Crescera Educacional.
  • In addition, Bertelsmann has had Daulins Emilio, the Managing Director at Bertelsmann Brazil Investments (BBI) and Head of the Bertelsmann Corporate Center in Brazil, as representative on Afyas board since 2019.
  • As a result of the closing of the transaction, Daniel Borghi and Laura Guaran from Crescera ceased to be Afya board members.
  • Pursuant to Afyas amended and restated articles of association, Shobhna Mohn and Kay Krafft were appointed by Bertelsmann as board members.

Abingdon Health Notes Announcement by UK-RTC on providing an Antibody Certificate using smartphone App technology

Retrieved on: 
Monday, April 19, 2021
COVID-19 pandemic in the United Kingdom, UK Rapid Test Consortium, Antibody, Public key certificate, Google Workspace, BBI, Branches of biology, Medicine, Biology

Testing can take place in a wide range of environments such as at a high-street pharmacy or workplace testing by a trained user.

Key Points: 
  • Testing can take place in a wide range of environments such as at a high-street pharmacy or workplace testing by a trained user.
  • Whilst performing the test, the trained user takes a picture of the individual to create a secure antibody certificate.\nBased on the Apple and Google approach for boarding passes, users will not need to install any new apps thanks to the new feature being built using a trusted existing interface compatible with all smartphones.
  • The QR code will be stored in the wallet feature of the smartphone, allowing the individual to control access to their personal results.\nThe antibody certificate solution has been developed by BBI Solutions, a member of the UK-RTC, using their Novarum\xe2\x84\xa2\xef\xb8\x8f technology.\nNeil Polwart Head of Mobile Solutions at BBI said:\n\xe2\x80\x9cAs diagnostics moves ever closer to the patient, we saw a new challenge of enabling the patient to carry their test result with them.
  • We wanted to do this in a way which would not require the patient to install any new apps or anyone checking the certificate to need special software, so that people could be assured we had privacy as the priority.\xe2\x80\x9d\nFor more information please contact:\n'